CoreRx to formulate and manufacture JanOne’s peripheral artery disease candidate
JanOne has signed a manufacturing agreement with cGMP contract manufacturer CoreRx for the clinical formulation and manufacturing of its lead drug candidate TV1001SR, a potential ... Read More
Amarin bags Vascepa FDA approval for reducing cardiovascular risk
Vascepa FDA approval : New Jersey-based Amarin has secured approval from the US Food and Drug Administration (FDA) for a new indication and label expansion ... Read More
Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease
Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase 1/2a clinical study, dubbed SHIELD, for its ... Read More